Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Recruiting · NCT06988605 · Observational (researchers observe without assigning treatment) · Lead sponsor: Galderma R&D

View the official record on ClinicalTrials.gov →

What this trial is about

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Who can take part

Age range

12 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

Inclusion criteria

Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.

Exclusion criteria

Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
Participants who received nemolizumab previously.
Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Where it is running

60 locations listed across 23 US states.

Galderma Investigational Site - 8893 - Birmingham, Alabama, United States
Galdrma Investigational Site - 7077 - Phoenix, Arizona, United States
Galderma Investigational Site 7060 - Phoenix, Arizona, United States
Galderma Investigational Site - 8535 - Phoenix, Arizona, United States
Galderma Investigational Site - 7067 - Tucson, Arizona, United States
Galderma Investigational Site - 7074 - Corona, California, United States
Galderma Investigational Site 8636 - Fountain Valley, California, United States
Galderma Investigational Site 8224 - Fremont, California, United States
Galderma Investigational Site 7099 - Los Angeles, California, United States
Galderma Investigational Site 8553 - Newport Beach, California, United States
Galderma Investigational Site 7064 - Santa Monica, California, United States
Galderma Investigational Site 7107 - Thousand Oaks, California, United States
Galderma Investigational Site 7061 - Castle Rock, Colorado, United States
Galderma Investigational Site 7059 - Fairfield, Connecticut, United States
Galderma Investigational Site 8597 - Boca Raton, Florida, United States
Galderma Investigational Site 7087 - Coral Gables, Florida, United States
Galderma Investigational Site 7063 - Cutler Bay, Florida, United States
Galderma Investigational Site 7134 - Hollywood, Florida, United States
Galderma Investigational Site 7101 - Jupiter, Florida, United States
Galderma Investigational Site 7078 - Miami, Florida, United States
Galderma Investigational Site 7070 - North Miami Beach, Florida, United States
Galderma Investigational Site 7112 - Oakland Park, Florida, United States
Galderma Investigational Site 7090 - St. Petersburg, Florida, United States
Galderma Investigational Site 7054 - Tampa, Florida, United States
Galderma Investigational Site 7058 - Chicago, Illinois, United States
Galderma Investigational Site 8142 - Indianapolis, Indiana, United States
Galderma Investigational Site 7083 - West Lafayette, Indiana, United States
Galderma Investigational Site 7098 - Columbia, Maryland, United States
Galderma Investigational Site 8012 - Glenn Dale, Maryland, United States
Galderma Investigational Site 7068 - Rockville, Maryland, United States
Galderma Investigational Site 7065 - Brighton, Massachusetts, United States
Galderma Investigationa Site 7104 - Milford, Massachusetts, United States
Galderma Investigational Site 7066 - Auburn Hills, Michigan, United States
Galderma Investigational Site 7071 - Caledonia, Michigan, United States
Galderma Investigational Site 7108 - Grandville, Michigan, United States
Galderma Investigational Site 7072 - Troy, Michigan, United States
Galderma Investigational Site 7057 - Lee's Summit, Missouri, United States
Galderma Investigational Site 8848 - Las Vegas, Nevada, United States
Galderma Investigational Site 7055 - Portsmouth, New Hampshire, United States
Galderma Investigational Site - Site 7080 - Auburn, New York, United States
Galderma Investigational Site # 7052 - East Syracuse, New York, United States
Galderma Investigational Site - 8282 - Mount Kisco, New York, United States
Galderma Investigational Site - 7051 - New York, New York, United States
Galderma Investigational Site 7109 - New York, New York, United States
Galderma Investigational Site 8279 - New York, New York, United States
Galderma Investigational Site 7081 - Dayton, Ohio, United States
Galderma Investigational Site 7073 - Gresham, Oregon, United States
Galderma Investigational Site 8559 - Philadelphia, Pennsylvania, United States
Galderma Investigational Site 7103 - Philadelphia, Pennsylvania, United States
Galderma Investigational Site 7106 - Bluffton, South Carolina, United States
Galderma Investigational Site 7082 - Cedar Park, Texas, United States
Galderma Investigational Site 8238 - Dallas, Texas, United States
Galderma Investigational Site 7062 - Edinburg, Texas, United States
Galderma Investigational Site 7088 - Grapevine, Texas, United States
Galderma Investigational Site 7069 - Sugar Land, Texas, United States
Galderma Investigational Site 8618 - Waco, Texas, United States
Galderma Investigational Site 7085 - Bountiful, Utah, United States
Galderma Investigational Site 7079 - Vienna, Virginia, United States
Galderma Investigational Site 8725 - Morgantown, West Virginia, United States
Galderma Investigational Site 6387 - Ahaus, Germany

Showing 60 of 108 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →